Base de dados : MEDLINE
Pesquisa : C04.557.470.200.025.060 [Categoria DeCS]
Referências encontradas : 3343 [refinar]
Mostrando: 1 .. 10   no formato [Detalhado]

página 1 de 335 ir para página                         

  1 / 3343 MEDLINE  
              next record last record
seleciona
para imprimir
Fotocópia
[PMID]:29244941
[Au] Autor:Ivanov YD; Malsagova KA; Pleshakova TO; Vesnin SG; Tatur VY; Yarygin KN
[Ti] Título:Monitoring of brightness temperature of suspension of follicular thyroid carcinoma cells in SHF range by radiothermometry.
[So] Source:Patol Fiziol Eksp Ter;60(4):174-7, 2016 Oct-Dec.
[Is] ISSN:0031-2991
[Cp] País de publicação:Russia (Federation)
[La] Idioma:eng
[Ab] Resumo:The purpose: The purpose of this research consisted in monitoring of brightness temperature of the suspension of follicular thyroid carcinoma cells during the necrosis of these cells in superhigh frequency (SHF) range. Methods: The monitoring of the change in the ratio between brightness temperatures TSHF and TIR values during the necrosis of these cells. The object of study was follicular thyroid carcinoma cells suspension prepared with use of Versene solution and 0.25% trypsin solution. The cells were precipitated by centrifugation and re-suspended in culture medium. The measurements of brightness temperatures were carried out with use of radiothermoimeter. SHF range was 3.4-4.2 GHz, and infrared (IR) range was 8-13 mm. The temperature of the suspension was maintained at 37.5°Ð¡. Results: It was found that upon the necrosis in the suspension of cells, an increase in brightness temperature in 3.4-4.2 GHz range (SHF range) occurs, while brightness temperature of the medium in the IR range does not change. Conclusion: The monitoring of necrosis of follicular thyroid carcinoma cells was carried out by SHF-radiothermometry. It was shown that during the necrosis the change of non-equilibrium state of cell medium occurs, that results in the change in the ratio between TSHF and TIR. During the necrosis, the brightness temperature in SHF range (TSHF) increases.
[Mh] Termos MeSH primário: Adenocarcinoma Folicular/metabolismo
Adenocarcinoma Folicular/patologia
Ondas de Rádio
Termometria/métodos
Neoplasias da Glândula Tireoide/metabolismo
Neoplasias da Glândula Tireoide/patologia
[Mh] Termos MeSH secundário: Linhagem Celular Tumoral
Seres Humanos
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Em] Mês de entrada:1801
[Cu] Atualização por classe:180118
[Lr] Data última revisão:
180118
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:171216
[St] Status:MEDLINE


  2 / 3343 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29235817
[Au] Autor:Guda BB; Pushkarev VV; Zhuravel OV; Kovalenko AY; Pushkarev VM; Taraschenko YM; Tronko MD
[Ti] Título:Protein kinase Akt activity in human thyroid tumors.
[So] Source:Ukr Biochem J;88(5):90-5, 2016 Sep-Oct.
[Is] ISSN:2409-4943
[Cp] País de publicação:Ukraine
[La] Idioma:eng
[Ab] Resumo:We studied the expression and activation of the main effector protein kinase of phosphatidylinositol-3-kinase cascade (PI3K) ­ Akt in conventionally normal tissues, benign and highly differentiated (with and without metastases) human thyroid tumors. There was a difference in the Akt1 amount in tumor tissue compared with normal tissue in papillary carcinomas and tissue of multinodular goiter. Akt expression both in tumor and conventionally normal tissues of follicular adenoma was significantly lower than in follicular carcinoma. The lowest level of Akt expression was observed in tissues of multinodular goiter. Total activity of all three isoforms of Akt1/2/3 was lower in tumors compared to conventionally normal tissue. Thus, Akt activity (according to Thr308 phosphorylation) is not associated with proliferative processes in the tumor tissue of the thyroid. Apoptosis level detected in these tissues was not associated with the protein kinase activity either. Possible mechanisms of signaling cascade PI3K/Akt inhibition in thyroid tumors are discussed.
[Mh] Termos MeSH primário: Adenocarcinoma Folicular/genética
Adenoma/genética
Carcinoma Papilar/genética
Bócio Nodular/genética
Fosfatidilinositol 3-Quinases/genética
Proteínas Proto-Oncogênicas c-akt/genética
Neoplasias da Glândula Tireoide/genética
[Mh] Termos MeSH secundário: Adenocarcinoma Folicular/enzimologia
Adenocarcinoma Folicular/patologia
Adenocarcinoma Folicular/cirurgia
Adenoma/enzimologia
Adenoma/patologia
Adenoma/cirurgia
Apoptose
Carcinoma Papilar/enzimologia
Carcinoma Papilar/patologia
Carcinoma Papilar/cirurgia
Regulação Neoplásica da Expressão Gênica
Bócio Nodular/enzimologia
Bócio Nodular/patologia
Bócio Nodular/cirurgia
Seres Humanos
Fosfatidilinositol 3-Quinases/metabolismo
Fosforilação
Poli(ADP-Ribose) Polimerase-1/genética
Poli(ADP-Ribose) Polimerase-1/metabolismo
Proteínas Proto-Oncogênicas c-akt/metabolismo
Transdução de Sinais
Glândula Tireoide/enzimologia
Glândula Tireoide/patologia
Glândula Tireoide/cirurgia
Neoplasias da Glândula Tireoide/enzimologia
Neoplasias da Glândula Tireoide/patologia
Neoplasias da Glândula Tireoide/cirurgia
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
EC 2.4.2.30 (PARP1 protein, human); EC 2.4.2.30 (Poly (ADP-Ribose) Polymerase-1); EC 2.7.1.- (Phosphatidylinositol 3-Kinases); EC 2.7.11.1 (AKT1 protein, human); EC 2.7.11.1 (AKT2 protein, human); EC 2.7.11.1 (AKT3 protein, human); EC 2.7.11.1 (Proto-Oncogene Proteins c-akt)
[Em] Mês de entrada:1801
[Cu] Atualização por classe:180116
[Lr] Data última revisão:
180116
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:171214
[St] Status:MEDLINE
[do] DOI:10.15407/ubj88.05.090


  3 / 3343 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:27778073
[Au] Autor:Pradhan R; Agarwal A
[Ad] Endereço:Sikkim Manipal Institute of Medical Sciences, Gangtok, India. drromapradhan@yahoo.com.
[Ti] Título:Prognostic Impact of Further Treatments on Distant Metastasis in Patients with Minimally Invasive Follicular Thyroid Carcinoma: Verification Using Inverse Probability of Treatment Weighting.
[So] Source:World J Surg;41(4):1143, 2017 04.
[Is] ISSN:1432-2323
[Cp] País de publicação:United States
[La] Idioma:eng
[Mh] Termos MeSH primário: Adenocarcinoma Folicular
Neoplasias da Glândula Tireoide
[Mh] Termos MeSH secundário: Carcinoma Papilar
Seres Humanos
Probabilidade
Prognóstico
[Pt] Tipo de publicação:LETTER; COMMENT
[Em] Mês de entrada:1712
[Cu] Atualização por classe:171211
[Lr] Data última revisão:
171211
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:161026
[St] Status:MEDLINE
[do] DOI:10.1007/s00268-016-3771-z


  4 / 3343 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28864536
[Au] Autor:Song YS; Lim JA; Min HS; Kim MJ; Choi HS; Cho SW; Moon JH; Yi KH; Park DJ; Cho BY; Park YJ
[Ad] Endereço:Department of Internal MedicineSeoul National University College of Medicine, Seoul National University Hospital, Seoul, Korea.
[Ti] Título:Changes in the clinicopathological characteristics and genetic alterations of follicular thyroid cancer.
[So] Source:Eur J Endocrinol;177(6):465-473, 2017 Dec.
[Is] ISSN:1479-683X
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:OBJECTIVE: Changes in the clinicopathological characteristics and genetic alterations of follicular thyroid cancer (FTC) over time have not been reported. Moreover, the prognostic effects of and promoter mutations in FTC have not been clearly elucidated. We investigated changes in the clinicopathological characteristics of patients with FTC over four decades, as well as the clinical significance of genetic mutations of FTC. DESIGN AND METHODS: This retrospective study included 690 patients with FTC who underwent thyroidectomy between 1973 and 2015 at the Seoul National University Hospital. In 134 samples, genetic tests for and promoter mutations and rearrangement were performed. RESULTS: The age at diagnosis has increased ( < 0.001) in recent decades and extrathyroidal extension of the tumor has become less common ( = 0.033). Other clinicopathological characteristics and prognosis of FTC have not significantly changed. The prevalence of mutations decreased ( = 0.042) over time, whereas that of promoter mutations remained stable. mutations were associated with distant metastasis and persistent disease, and promoter mutations were associated with distant metastasis, advanced TNM stage, recurrence and disease-specific mortality. FTC patients with coexistent and promoter mutations showed a higher recurrence risk than those with only one mutation. CONCLUSIONS: The age at diagnosis of FTC and the frequency of extrathyroidal extension have changed over four decades. Moreover, the prevalence of mutations decreased. and promoter mutations may be associated with poor clinical outcomes in FTC, especially when the two mutations coexist.
[Mh] Termos MeSH primário: Adenocarcinoma Folicular/genética
GTP Fosfo-Hidrolases/genética
Proteínas de Membrana/genética
Mutação
Proteínas Proto-Oncogênicas p21(ras)/genética
Telomerase/genética
Glândula Tireoide/patologia
Neoplasias da Glândula Tireoide/genética
[Mh] Termos MeSH secundário: Adenocarcinoma Folicular/diagnóstico
Adenocarcinoma Folicular/metabolismo
Adenocarcinoma Folicular/patologia
Fatores Etários
Códon
Feminino
GTP Fosfo-Hidrolases/metabolismo
Transição Epidemiológica
Seres Humanos
Masculino
Proteínas de Membrana/metabolismo
Meia-Idade
Taxa de Mutação
Proteínas de Neoplasias/genética
Proteínas de Neoplasias/metabolismo
Estadiamento de Neoplasias
Prognóstico
Regiões Promotoras Genéticas
Proteínas Proto-Oncogênicas p21(ras)/metabolismo
Estudos Retrospectivos
Seul
Telomerase/metabolismo
Glândula Tireoide/metabolismo
Neoplasias da Glândula Tireoide/diagnóstico
Neoplasias da Glândula Tireoide/metabolismo
Neoplasias da Glândula Tireoide/patologia
Carga Tumoral
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Codon); 0 (Membrane Proteins); 0 (Neoplasm Proteins); EC 2.7.7.49 (TERT protein, human); EC 2.7.7.49 (Telomerase); EC 3.6.1.- (GTP Phosphohydrolases); EC 3.6.1.- (NRAS protein, human); EC 3.6.5.2 (HRAS protein, human); EC 3.6.5.2 (Proto-Oncogene Proteins p21(ras))
[Em] Mês de entrada:1710
[Cu] Atualização por classe:171020
[Lr] Data última revisão:
171020
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170903
[St] Status:MEDLINE
[do] DOI:10.1530/EJE-17-0456


  5 / 3343 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28858122
[Au] Autor:Kuo SF; Ho TY; Liou MJ; Lin KJ; Cheng RC; Chan SC; Huang BY; Ng SC; Liu FH; Chang HY; Hsieh SH; Chiang KC; Chen HY; Lo TY; Lin CL; Lin JD
[Ad] Endereço:aDepartment of Endocrinology and Metabolism, Chang Gung Memorial Hospital, Keelung bChang Gung University, College of Medicine cDepartment of Nuclear Medicine dDepartment of Endocrinology and Metabolism, Chang Gung Memorial Hospital, Kwei-Shan, Taoyuan eDepartment of Nuclear Medicine fDepartment of General Surgery gDepartment of Gastroenterology, Chang Gung Memorial Hospital, Keelung, Taiwan.
[Ti] Título:Higher body weight and distant metastasis are associated with higher radiation exposure to the household environment from patients with thyroid cancer after radioactive iodine therapy.
[So] Source:Medicine (Baltimore);96(35):e7942, 2017 Sep.
[Is] ISSN:1536-5964
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:There were insufficient data regarding radiation exposure to the household environment from patients with thyroid cancer who received radioactive iodine (RAI) therapy in Asia; we therefore performed the present study at the Chang Gung Memorial Hospital in Keelung, Taiwan.Patients with papillary or follicular thyroid cancer who received 3.7 GBq (100 mCi) RAI were enrolled in this prospective hospital-based study. The enrolled patients were asked to place a thermoluminescent dosimeter in the living room, bedroom, and bathroom of their houses for 4 weeks to measure radiation exposure to the household environment.A total of 43 patients (18 men and 25 women; mean age 51 ±â€Š13 years) who received 3.7 GBq (100 mCi) RAI completed the study. The mean value of total radiation exposure over 4 weeks from the patients to the bedroom, bathroom, and living room (eliminating the background radiation factor) was 0.446 ±â€Š0.304 (0.088-1.382) mSv. We divided the patients into 2 groups: those with more than and less than the mean value of total radiation exposure to the bedroom, bathroom, and living room. Factors associated with the higher amount of radiation exposure from the patients to the household environment were patient body weight (P = .025, univariate analysis; P = .037, multivariate analysis, odds ratio [95% confidence interval] 1.067 [1.004-1.134]) and distant metastases based on I post-therapy scanning (P = .041, univariate analysis; P = .058, multivariate analysis, odds ratio [95% confidence interval] 6.453 [0.938-44.369]); age, sex, body mass index, renal function, serum stimulated thyroglobulin level, and recombinant human thyroid-stimulating hormone use were not associated with the amount of radiation exposure from the patients to the household environment.Higher body weight and distant metastases may be the best predictors for higher radiation exposure to the household environment from patients with thyroid cancer after RAI therapy.
[Mh] Termos MeSH primário: Adenocarcinoma Folicular/radioterapia
Peso Corporal
Carcinoma Papilar/radioterapia
Radioisótopos do Iodo/uso terapêutico
Exposição à Radiação
Neoplasias da Glândula Tireoide/radioterapia
[Mh] Termos MeSH secundário: Adenocarcinoma Folicular/patologia
Adulto
Idoso
Carcinoma Papilar/patologia
Cuidadores
Família
Feminino
Seres Humanos
Masculino
Meia-Idade
Metástase Neoplásica
Estudos Prospectivos
Dosimetria Termoluminescente
Neoplasias da Glândula Tireoide/patologia
[Pt] Tipo de publicação:JOURNAL ARTICLE; OBSERVATIONAL STUDY
[Nm] Nome de substância:
0 (Iodine Radioisotopes)
[Em] Mês de entrada:1709
[Cu] Atualização por classe:170918
[Lr] Data última revisão:
170918
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:170901
[St] Status:MEDLINE
[do] DOI:10.1097/MD.0000000000007942


  6 / 3343 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28821194
[Au] Autor:Farhat NA; Onenerk AM; Krane JF; Dias-Santagata D; Sadow PM; Faquin WC
[Ad] Endereço:Massachusetts General Hospital, Boston.
[Ti] Título:Primary Benign and Malignant Thyroid Neoplasms With Signet Ring Cells: Cytologic, Histologic, and Molecular Features.
[So] Source:Am J Clin Pathol;148(3):251-258, 2017 Sep 01.
[Is] ISSN:1943-7722
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:Objectives: Signet ring cells (SRCs) can be seen in a variety of thyroid tumors and can pose a diagnostic pitfall on cytology. This study describes the cytologic, histomorphologic, and molecular aspects of a cohort of primary thyroid tumors with SRCs. Methods: A search was performed of the Massachusetts General Hospital and Brigham and Women's Hospital (Boston, MA) pathology archives for the keywords thyroid, signet, and signet ring features between 2000 and 2014. Seven thyroidectomy specimens with corresponding thyroid fine-needle aspiration (FNA) were obtained. Cytology and histopathology slides were evaluated. Molecular analysis was performed using anchored multiplex polymerase chain reaction (AMP). Results: The cohort consisted of four follicular adenomas (FAs), two noninvasive follicular thyroid neoplasms with papillary-like nuclear features (NIFTPs), and one secretory carcinoma (SC). The FNA diagnoses were atypia of undetermined significance (n = 3), suspicious for follicular neoplasm (n = 3), and suspicious for malignancy (n = 1). Molecular analyses revealed PTEN and FGFR3 mutations in an FA and NIFTP, respectively, and an ETV6-NTRK3 fusion in a case of primary thyroid gland SC. Conclusions: Our study demonstrates the range of thyroid tumors with SRCs. While most thyroid tumors with SRCs are benign, primary thyroid SC should also be considered in the differential diagnosis.
[Mh] Termos MeSH primário: Adenocarcinoma Folicular/patologia
Adenoma/patologia
Neoplasias da Glândula Tireoide/patologia
[Mh] Termos MeSH secundário: Adenocarcinoma Folicular/metabolismo
Adenocarcinoma Folicular/cirurgia
Adenoma/metabolismo
Adenoma/cirurgia
Adolescente
Idoso
Idoso de 80 Anos ou mais
Biópsia por Agulha Fina
Diagnóstico Diferencial
Feminino
Seres Humanos
Masculino
Meia-Idade
Mutação
PTEN Fosfo-Hidrolase/metabolismo
Receptor Tipo 3 de Fator de Crescimento de Fibroblastos/metabolismo
Neoplasias da Glândula Tireoide/metabolismo
Neoplasias da Glândula Tireoide/cirurgia
Tireoidectomia
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
EC 2.7.10.1 (FGFR3 protein, human); EC 2.7.10.1 (Receptor, Fibroblast Growth Factor, Type 3); EC 3.1.3.67 (PTEN Phosphohydrolase); EC 3.1.3.67 (PTEN protein, human)
[Em] Mês de entrada:1709
[Cu] Atualização por classe:170906
[Lr] Data última revisão:
170906
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:170820
[St] Status:MEDLINE
[do] DOI:10.1093/ajcp/aqx074


  7 / 3343 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28821191
[Au] Autor:Renshaw AA; Gould EW
[Ad] Endereço:Department of Pathology, Baptist Hospital, Miami, FL.
[Ti] Título:Impact of Noninvasive Follicular Thyroid Neoplasm With Papillary-Like Features on Adequacy Criteria and Risk of Malignancy of Thyroid Fine-Needle Aspiration.
[So] Source:Am J Clin Pathol;148(3):259-263, 2017 Sep 01.
[Is] ISSN:1943-7722
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:Objectives: The impact of noninvasive follicular thyroid neoplasm with papillary-like features (NIFTP) on nondiagnostic and benign diagnoses is not well characterized. Methods: The results of all thyroid fine-needle aspirates (FNAs) performed from 1997 to June 2016 with corresponding resections were reviewed. Results: From 12,764 aspirates, there were 8,106 (64%) benign diagnoses with 412 (5%) resections and 1,888 (14.8%) nondiagnostic diagnoses with 329 (17%) resections. Before the use of NIFTP, there were 18 (4.3%) malignancies in the benign aspirates and 39 (11.9%) malignancies in the nondiagnostic aspirates. There were 12 NIFTP cases on review. After reclassification using NIFTP, there were 10 of 412 (2.4%) malignancies in the benign aspirates. When cases with 10 to 60 benign follicle cells without atypia or Hürthle cell change were reclassified as benign rather than nondiagnostic, the malignancy rate for a benign aspirate decreased (12/506, 2.3%; P = 1.0) when NIFTP cases were recognized. Conclusions: With NIFTP, reducing the threshold for adequacy from 60 to 10 cells led to nonsignificant decrease in the risk of malignancy of a benign diagnosis (2.4% to 2.3%). Thyroid fine-needle aspirates with 10 to 60 benign cells without atypia or Hürthle cell change should be diagnosed as benign.
[Mh] Termos MeSH primário: Adenocarcinoma Folicular/patologia
Carcinoma Papilar/patologia
Glândula Tireoide/patologia
Neoplasias da Glândula Tireoide/patologia
[Mh] Termos MeSH secundário: Biópsia por Agulha Fina
Seres Humanos
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Em] Mês de entrada:1709
[Cu] Atualização por classe:170906
[Lr] Data última revisão:
170906
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:170820
[St] Status:MEDLINE
[do] DOI:10.1093/ajcp/aqx068


  8 / 3343 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28719972
[Au] Autor:Lee JH; Han K; Kim EK; Moon HJ; Yoon JH; Park VY; Kwak JY
[Ad] Endereço:1 Department of Radiology, Severance Hospital, Research Institute of Radiological Science, Yonsei University, College of Medicine, Seoul, Korea.
[Ti] Título:Risk Stratification of Thyroid Nodules With Atypia of Undetermined Significance/Follicular Lesion of Undetermined Significance (AUS/FLUS) Cytology Using Ultrasonography Patterns Defined by the 2015 ATA Guidelines.
[So] Source:Ann Otol Rhinol Laryngol;126(9):625-633, 2017 Sep.
[Is] ISSN:1943-572X
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:PURPOSE: The purpose of this study was to evaluate the predictive value of ultrasonography (US) patterns based on the 2015 American Thyroid Association (ATA) guidelines for malignancy in atypia of undetermined significance or follicular lesion of undetermined significance (AUS/FLUS) nodules. METHODS: From January 2014 to August 2015, 133 thyroid nodules that were initially diagnosed as AUS/FLUS on fine needle aspiration (FNA) were included in this study. Each nodule was assigned a category with US patterns defined by the ATA guidelines. Clinical characteristics and US patterns were compared between the benign and malignant nodules, and malignancy rates were calculated according to the ATA guidelines. RESULTS: The malignancy rate in the very low suspicion group was 0.0% in AUS/FLUS nodules. When applying the ATA guidelines, significant differences existed for US patterns between the benign and malignant nodules in the AUS group ( P = .032) but not the FLUS group ( P = .168). CONCLUSIONS: Ultrasonography patterns by the 2015 ATA guidelines can provide risk stratification for nodules with AUS cytology but not for ones with FLUS cytology. For nodules with AUS/FLUS cytology with the very low suspicion pattern of the ATA guidelines, follow-up US might be recommended instead of repeat FNA.
[Mh] Termos MeSH primário: Adenocarcinoma Folicular/diagnóstico por imagem
Adenoma/diagnóstico por imagem
Carcinoma Neuroendócrino/diagnóstico por imagem
Carcinoma/diagnóstico por imagem
Neoplasias da Glândula Tireoide/diagnóstico por imagem
Nódulo da Glândula Tireoide/diagnóstico por imagem
Tireoidite Autoimune/diagnóstico por imagem
Tireoidite Subaguda/diagnóstico por imagem
[Mh] Termos MeSH secundário: Adenocarcinoma Folicular/patologia
Adenoma/patologia
Adulto
Biópsia por Agulha Fina
Carcinoma/patologia
Carcinoma Neuroendócrino/patologia
Carcinoma Papilar
Feminino
Seres Humanos
Hiperplasia
Masculino
Meia-Idade
Guias de Prática Clínica como Assunto
Estudos Retrospectivos
Medição de Risco
Neoplasias da Glândula Tireoide/patologia
Nódulo da Glândula Tireoide/patologia
Tireoidite Autoimune/patologia
Tireoidite Subaguda/patologia
Ultrassonografia
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Em] Mês de entrada:1708
[Cu] Atualização por classe:171116
[Lr] Data última revisão:
171116
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:170720
[St] Status:MEDLINE
[do] DOI:10.1177/0003489417719472


  9 / 3343 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo SciELO Brasil
[PMID]:28699989
[Au] Autor:Leite AKN; Cavalheiro BG; Kulcsar MA; Hoff AO; Brandão LG; Cernea CR; Matos LL
[Ad] Endereço:Divisão de Cirurgia de Cabeça e Pescoço, Faculdade de Medicina da Universidade de São Paulo (FMUSP) e Instituto do Câncer do Estado de São Paulo (ICESP), São Paulo, SP, Brasil.
[Ti] Título:Deaths related to differentiated thyroid cancer: a rare but real event.
[So] Source:Arch Endocrinol Metab;61(3):222-227, 2017 May-Jun.
[Is] ISSN:2359-4292
[Cp] País de publicação:Brazil
[La] Idioma:eng
[Ab] Resumo:Objective: The present study describes the clinical and tumor characteristics of patients that died from differentiated thyroid cancer and reports on the cause and circumstances of death in these cases. Subjects and methods: Retrospective analysis of all the differentiated thyroid cancer (DTC) related deaths at a single institution over a 5-year period, with a total of 33 patients. Results: Most of the patients were female (63.6%), with a mean age at diagnosis of 58.2 years. The most common histologic type was papillary (66.7%) and 30.3% were follicular. The distribution according to the TNM classification was: 15.4% of T1; 7.7% T2; 38.4% T3; 19.2% of T4a and 19.2% of T4b. Forty-four percent of cases were N0; 20% N1a and 36.6% of N1b. Twelve patients were considered non-responsive to radioiodine. Only one of the patients did not have distant metastases. The most common metastatic site was the lung in 69.7%. The majority of deaths were due to pulmonary complications related to lung metastases (17 patients, 51.5%), followed by post-operative complications in 5 cases, neurological disease progression in 3 cases, local invasion and airway obstruction in one patient. Median survival between diagnosis and death was reached in 49 months while between disease progression and death it was at 22 months. Conclusion: Mortality from DTC is extremely rare but persists, and the main causes of death derive from distant metastasis, especially respiratory failure due to lung metastasis. Once disease progression is established, median survival was only 22 months.
[Mh] Termos MeSH primário: Adenocarcinoma Folicular/mortalidade
Carcinoma Papilar/mortalidade
Neoplasias da Glândula Tireoide/mortalidade
[Mh] Termos MeSH secundário: Adenocarcinoma Folicular/patologia
Idoso
Brasil
Carcinoma Papilar/patologia
Causas de Morte
Progressão da Doença
Feminino
Seres Humanos
Estimativa de Kaplan-Meier
Neoplasias Pulmonares/secundário
Masculino
Meia-Idade
Estadiamento de Neoplasias
Estudos Retrospectivos
Fatores de Risco
Distribuição por Sexo
Neoplasias da Glândula Tireoide/patologia
Fatores de Tempo
Tomografia Computadorizada por Raios X
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Em] Mês de entrada:1709
[Cu] Atualização por classe:170925
[Lr] Data última revisão:
170925
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170713
[St] Status:MEDLINE


  10 / 3343 MEDLINE  
              first record previous record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28662274
[Au] Autor:Sherman EJ; Dunn LA; Ho AL; Baxi SS; Ghossein RA; Fury MG; Haque S; Sima CS; Cullen G; Fagin JA; Pfister DG
[Ad] Endereço:Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, New York.
[Ti] Título:Phase 2 study evaluating the combination of sorafenib and temsirolimus in the treatment of radioactive iodine-refractory thyroid cancer.
[So] Source:Cancer;123(21):4114-4121, 2017 Nov 01.
[Is] ISSN:1097-0142
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: Patients with recurrent and/or metastatic, radioactive iodine-refractory thyroid carcinoma have limited treatment options. Sorafenib, an oral kinase inhibitor, is approved by the US Food and Drug Administration for the treatment of radioactive iodine-refractory thyroid carcinoma, although it demonstrated low response rates (12.2%) as a single agent in the first-line setting. The objective of the current study was to determine whether adding the mammalian target of rapamycin inhibitor temsirolimus to sorafenib could improve on these results. METHODS: In this single-institution, phase 2 study, 36 patients with metastatic, radioactive iodine-refractory thyroid carcinoma of follicular origin received treatment with the combination of oral sorafenib (200 mg twice daily) and intravenous temsirolimus (25 mg weekly). The receipt of prior systemic treatment with cytotoxic chemotherapy and targeted therapy, including sorafenib, was permitted. The primary endpoint was the radiographic response rate. RESULTS: The best response was a partial response in 8 patients (22%), stable disease in 21 (58%), and progressive disease in 1 (3%). Six patients were not evaluable for a response. Patients who had received any prior systemic treatment had a response rate of 10% compared with 38% of those who had not received prior systemic treatment. One of 2 patients with anaplastic thyroid cancer had an objective response. The progression-free survival rate at 1 year was 30.5%. The most common grade 3 and 4 toxicities associated with sorafenib and temsirolimus included hyperglycemia, fatigue, anemia, and oral mucositis. CONCLUSIONS: Sorafenib and temsirolimus appear to be an active combination in patients with radioactive iodine-refractory thyroid carcinoma, especially in patients who received no prior treatment compared with historic data from single-agent sorafenib. Activity is also observed in patients who previously received sorafenib. This regimen warrants further investigation. Cancer 2017;123:4114-4121. © 2017 American Cancer Society.
[Mh] Termos MeSH primário: Adenocarcinoma Folicular/tratamento farmacológico
Antineoplásicos/uso terapêutico
Protocolos de Quimioterapia Combinada Antineoplásica/uso terapêutico
Niacinamida/análogos & derivados
Compostos de Fenilureia/administração & dosagem
Sirolimo/análogos & derivados
Neoplasias da Glândula Tireoide/tratamento farmacológico
[Mh] Termos MeSH secundário: Adenocarcinoma Folicular/genética
Adenocarcinoma Folicular/patologia
Adenocarcinoma Folicular/radioterapia
Adulto
Idoso
Idoso de 80 Anos ou mais
Antineoplásicos/efeitos adversos
Protocolos de Quimioterapia Combinada Antineoplásica/efeitos adversos
Intervalo Livre de Doença
Esquema de Medicação
Feminino
Seres Humanos
Radioisótopos do Iodo/uso terapêutico
Masculino
Meia-Idade
Mutação
Niacinamida/administração & dosagem
Niacinamida/efeitos adversos
Compostos de Fenilureia/efeitos adversos
Proteínas Proto-Oncogênicas B-raf/genética
Tolerância a Radiação
Sirolimo/administração & dosagem
Sirolimo/efeitos adversos
Neoplasias da Glândula Tireoide/genética
Neoplasias da Glândula Tireoide/patologia
Neoplasias da Glândula Tireoide/radioterapia
Resultado do Tratamento
[Pt] Tipo de publicação:CLINICAL TRIAL, PHASE II; JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Antineoplastic Agents); 0 (Iodine Radioisotopes); 0 (Phenylurea Compounds); 25X51I8RD4 (Niacinamide); 624KN6GM2T (temsirolimus); 9ZOQ3TZI87 (sorafenib); EC 2.7.11.1 (BRAF protein, human); EC 2.7.11.1 (Proto-Oncogene Proteins B-raf); W36ZG6FT64 (Sirolimus)
[Em] Mês de entrada:1710
[Cu] Atualização por classe:171030
[Lr] Data última revisão:
171030
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:170630
[St] Status:MEDLINE
[do] DOI:10.1002/cncr.30861



página 1 de 335 ir para página                         
   


Refinar a pesquisa
  Base de dados : MEDLINE Formulário avançado   

    Pesquisar no campo  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/OPAS/OMS - Centro Latino-Americano e do Caribe de Informação em Ciências da Saúde